Drug Trial Radar · NCT07444580
PrP-targeting siRNA Safety & Mechanism Study
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
May 15, 2026
Primary completion
Aug 14, 2029
Study completion Aug 14, 2029
Sponsor
- Lead sponsor
- Broad Institute of MIT and HarvardAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS)
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic impact of PrP-siRNA in symptomatic prion disease patients and in pre-symptomatic adults at genetic risk for prion disease.
Conditions
- Prion Disease
Interventions
PrP-siRNADrug
Intrathecally administered divalent siRNA designed to target the PRNP mRNA. The structure has been published in PMID: 42033217
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of adverse eventsTime frame: Baseline to week 24
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.